In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Safer Officers and Safer Citizens 
Act of 2017''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) While police body worn cameras are not a panacea, they 
        do contribute to keeping both law enforcement officers and 
        citizens safer.
            (2) Increasing the use of body worn cameras by law 
        enforcement officers has been shown by multiple studies to 
        significantly reduce the number of use of force incidents and 
        the number of citizen complaints.
            (3) Increased accountability and transparency in policing 
        activities will benefit all our citizens, including our law 
        enforcement officers.

SEC. 3. GRANT PROGRAM.

    Title I of the Omnibus Crime Control and Safe Streets Act of 1968 
(42 U.S.C. 3711 et seq.) is amended by adding at the end the following:

  ``PART MM--GRANT PROGRAM FOR BODY WORN CAMERAS FOR LAW ENFORCEMENT 
                                OFFICERS

``SEC. 3031. PROGRAM AUTHORIZED.

    ``(a) In General.--The Director of the Bureau of Justice Assistance 
is authorized to make grants to States, units of local government, and 
Indian tribes to purchase body worn cameras for use by State, local, 
and tribal law enforcement officers.
    ``(b) Uses of Funds.--Grants awarded under this section shall be--
            ``(1) distributed directly to the State, unit of local 
        government, or Indian tribe; and
            ``(2) used for the purchase of--
                    ``(A) body worn cameras for law enforcement 
                officers; and
                    ``(B) necessary initial supportive technological 
                infrastructure for body worn cameras for law 
                enforcement officers in the jurisdiction of the 
                grantee.
    ``(c) Preferential Consideration.--In awarding grants under this 
part, the Director of the Bureau of Justice Assistance shall give 
preferential consideration, if feasible, to an application from a 
jurisdiction that--
            ``(1) has in place a comprehensive policy that is--
                    ``(A) developed in consultation with a broad group 
                of criminal justice experts and community members, and 
                that contains policies and procedures addressing 
                deployment, video capture, privacy protections, 
                viewing, use, release, storage, retention, the effect 
                on community-police interactions, and audits and 
                controls;
                    ``(B) supported by a comprehensive communication 
                and education campaign that involves interested parties 
                in law enforcement, courts, prosecution, the defense 
                bar, civic leadership, labor organizations, victim and 
                juvenile advocacy, the media, and the public; and
                    ``(C) informed by the best practices on body worn 
                cameras developed by the Department of Justice;
            ``(2) has the greatest need for body worn cameras based on 
        the percentage of law enforcement officers in the department 
        who do not have access to a body worn camera;
            ``(3) has a violent crime rate at or above the national 
        average as determined by the Bureau of Justice Statistics; and
            ``(4) commits to submitting such metrics on the usage of 
        body worn cameras, in such a format and at such a time as the 
        Department of Justice shall reasonably specify, for the 
        purposes of collecting and studying data on the effectiveness 
        of body worn cameras to increase safety for both law 
        enforcement officers and citizens.
    ``(d) Matching Funds.--The portion of the costs of a program 
provided by a grant under subsection (a) may not exceed 75 percent. Any 
funds appropriated by Congress for the activities of any agency of an 
Indian tribal government or the Bureau of Indian Affairs performing law 
enforcement functions on any Indian lands may be used to provide the 
non-Federal share of a matching requirement funded under this 
subsection.

``SEC. 3032. APPLICATIONS.

    ``(a) In General.--To request a grant under this part, the chief 
executive of a State, unit of local government, or Indian tribe shall 
submit an application to the Director of the Bureau of Justice 
Assistance in such form and containing such information as the Director 
may reasonably require.
    ``(b) Regulations.--Not later than 90 days after the date of the 
enactment of this part, the Director of the Bureau of Justice 
Assistance shall promulgate regulations to implement this section, 
including the information that must be included and the requirements 
that the States, units of local government, and Indian tribes must meet 
in submitting the applications required under this section.

``SEC. 3033. DEFINITIONS.

    ``For purposes of this part--
            ``(1) the term `Indian tribe' has the same meaning as in 
        section 4(e) of the Indian Self-Determination and Education 
        Assistance Act (25 U.S.C. 450b(e));
            ``(2) the term `law enforcement officer' means any officer, 
        agent, or employee of a State, unit of local government, or 
        Indian tribe authorized by law or by a government agency to 
        engage in or supervise the prevention, detection, or 
        investigation of any violation of criminal law, or authorized 
        by law to supervise sentenced criminal offenders;
            ``(3) the term `State' means each of the 50 States, the 
        District of Columbia, the Commonwealth of Puerto Rico, the 
        United States Virgin Islands, American Samoa, Guam, and the 
        Northern Mariana Islands; and
            ``(4) the term `unit of local government' means a county, 
        municipality, town, township, village, parish, borough, or 
        other unit of general government below the State level.

``SEC. 3034. AUTHORIZATION OF APPROPRIATIONS.

    ``(a) In General.--There are authorized to be appropriated to carry 
out this part, $100,000,000 for each of fiscal years 2018 through 2022.
    ``(b) Remaining Funds.--Any amounts made available to carry out 
this part that are unobligated at the end of each fiscal year, shall be 
returned to the general fund of the Treasury for debt reduction.''.

SEC. 4. OFFSET.

    (a) Findings.--Congress finds the following:
            (1) In 2010, the most current year for which figures are 
        available, the Federal Government spent $1,670,000,000 
        operating and maintaining unutilized and underutilized 
        buildings.
            (2) Federal agencies have consistently indicated that the 
        disposal efforts of the agencies are often hampered by 
        statutory requirements.
    (b) Offset.--Notwithstanding subtitle I of title 40, United States 
Code, or any other provision of law, the Administrator of General 
Services, in consultation with the Director of the Office of Management 
and Budget, may immediately identify and dispose of, through sale at 
fair market value or demolition if unsuitable for sale, the most 
financially burdensome excess Federal property, so as to generate not 
more than $500,000,000 in savings by the end of fiscal year 2022.

A: Safer Officers and Safer Citizens Act of 2017 This bill amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Department of Justice's Bureau of Justice Assistance to award matching grants to states, local governments, and Indian tribes to purchase body-worn cameras.  The Bureau of Justice Assistance must give preference to grant applications from jurisdictions that: (1) have comprehensive policies and procedures related to implementation of a body-worn camera program, (2) have high percentages of officers without access to body-worn cameras, (3) have violent crime rates above the national average, and (4) agree to submit metrics on the use of body-worn cameras.  As an offset, the bill allows the General Services Administration to identify and dispose of (i.e., sell or demolish) excess federal property. 
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Helping Effective Antibiotics Last 
Act of 2015'' or the ``HEAL Act''.

SEC. 2. APPROVAL OF CERTAIN DRUGS FOR USE IN A WELL-DEFINED POPULATION 
              OF PATIENTS.

    (a) Approval of Certain Antibacterial.--Section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at 
the end the following:
    ``(x) Approval of Certain Antibacterial Drugs for Use in a Well-
Defined Population of Patients.--
            ``(1) Unmet medical need defined.--In this subsection, the 
        term `unmet medical need' means that the antibacterial drug 
        involved--
                    ``(A) has improved efficacy, as demonstrated in 
                adequate, well-controlled studies in humans, for 
                specific diseases or conditions, where current 
                therapies have been shown to be less effective;
                    ``(B) has clinically meaningful decreased harms, 
                demonstrated in adequate, well-controlled studies in 
                humans, for diseases or conditions, where current 
                therapies have unacceptable adverse effects; or
                    ``(C) has improved convenience, as demonstrated in 
                adequate, well-controlled studies in humans, where 
                improved convenience results in improved effectiveness 
                or decreased harms.
            ``(2) Approval.--Upon receipt of an application under 
        subsection (b) for an antibacterial drug that is intended to 
        treat a serious or life-threatening disease or condition, 
        irrespective of whether the drug is intended to address an 
        unmet medical need, the Secretary--
                    ``(A) may approve the drug under subsection (c) 
                only for treating a well-defined population of 
                patients, and based upon the results of clinical trials 
                inclusive of human subjects representative of such 
                well-defined population;
                    ``(B) in determining whether to grant such 
                approval, shall rely on superior outcomes over 
                available therapies based on direct measures of patient 
                benefits, as demonstrated in adequate, well-controlled 
                studies in the well-defined patient population, such 
                as--
                            ``(i) decreased mortality;
                            ``(ii) irreversible morbidity; or
                            ``(iii) validated surrogate endpoints that 
                        reflect mortality or irreversible morbidity; 
                        and
                    ``(C) shall require the labeling of drugs approved 
                pursuant to this subsection to prominently include in 
                the prescribing information required by section 201.57 
                of title 21, Code of Federal Regulations (or any 
                successor regulation)--
                            ``(i) the population of patients with 
                        respect to which the added benefit over 
                        available therapies is expected as studied in 
                        adequate, well-controlled studies that form the 
                        basis for approval; and
                            ``(ii) the method for identifying members 
                        of that population.
            ``(3) Risk evaluation and mitigation strategy.--The 
        Secretary--
                    ``(A) shall require a risk evaluation and 
                mitigation strategy (REMS) under section 505-1 for each 
                drug approved under this subsection; and
                    ``(B) may include in any such strategy additional 
                elements to assure the safe use of the drug under 
                subsections (e) and (f) of section 505-1.
            ``(4) Rule of construction.--Nothing in this subsection 
        shall be construed to alter the standards of evidence under 
        subsection (c) or (d) (including the substantial evidence 
        standard in subsection (d)). Subsections (c) and (d) and such 
        standards of evidence apply to the review and approval of drugs 
        under this subsection, including whether a drug is safe and 
        effective. Nothing in this subsection shall be construed to 
        limit the authority of the Secretary to approve products 
        pursuant to this Act and the Public Health Service Act as 
        authorized prior to the date of enactment of this subsection.
            ``(5) Effective immediately.--The Secretary shall have the 
        authorities vested in the Secretary by this subsection 
        beginning on the date of enactment of this subsection, 
        irrespective of when and whether the Secretary promulgates 
        final regulations to carry out this subsection.''.
    (b) Licensure of Certain Biological Products.--Section 351(j) of 
the Public Health Service Act (42 U.S.C. 262(j)) is amended--
            (1) by striking ``(j)'' and inserting ``(j)(1)'';
            (2) by inserting ``505(x),'' after ``505(p),''; and
            (3) by adding at the end the following:
    ``(2) In applying section 505(x) of the Federal Food, Drug, and 
Cosmetic Act to the licensure of biological products under this 
section--
            ``(A) references to an antibacterial drug with added 
        benefits over available therapies for a well-defined population 
        that is intended to treat a serious or life-threatening disease 
        or condition shall be construed to refer to biological products 
        with added benefits over available therapies for a well-defined 
        population intended to treat a bacterial infection associated 
        with a serious or life-threatening disease; and
            ``(B) references to an application submitted under section 
        505(b) of such Act and to approval of a drug under section 
        505(c) of such Act shall be construed to refer to an 
        application submitted under subsection (a) of this section and 
        to licensure of a biological product under such subsection (a), 
        respectively.''.
    (c) Monitoring.--Title III of the Public Health Service Act is 
amended by inserting after section 317T (42 U.S.C. 247b-22) the 
following:

``SEC. 317U. MONITORING OF ANTIBACTERIAL DRUG USE, PATIENT OUTCOMES, 
              AND RESISTANCE.

    ``(a) Monitoring.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall use the National 
Healthcare Safety Network or another appropriate monitoring system to 
monitor--
            ``(1) changes in patient outcomes such as mortality and 
        irreversible morbidity causally related to antibacterial 
        resistance; and
            ``(2) changes in bacterial resistance to drugs in relation 
        to patient outcomes.
    ``(b) Public Availability of Data.--The Secretary, acting through 
the Director of the Centers for Disease Control and Prevention, shall 
make the data derived from monitoring under this section publicly 
available for the purposes of--
            ``(1) improving the monitoring of important trends in 
        patient outcomes in relation to antibacterial resistance; and
            ``(2) ensuring appropriate stewardship of antibacterial 
        drugs, including those receiving approval or licensure for a 
        well-defined population pursuant to section 505(x) of the 
        Federal Food, Drug, and Cosmetic Act.''.

SEC. 3. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL 
              ORGANISMS.

    (a) In General.--Section 511 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360a) is amended to read as follows:

``SEC. 511. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL 
              ORGANISMS.

    ``(a) In General.--The Secretary shall--
            ``(1) identify upon approval or licensing of antibacterial 
        drugs (including biological products intended to treat a 
        bacterial infection and other types of antimicrobial drugs, as 
        deemed appropriate by the Secretary), including qualified 
        infectious disease products, susceptibility test interpretive 
        criteria for such drugs based upon patient outcomes of 
        mortality and morbidity from adequate and well-controlled 
        studies and such other confirmatory evidence as the Secretary 
        deems necessary; and
            ``(2) update, consistent with subsection (b), such criteria 
        as needed based upon scientific evidence of changes in patient 
        outcomes.
    ``(b) Responding to Changes in Patient Outcomes To Evaluate 
Susceptibility Test Interpretive Criteria.--
            ``(1) In general.--As needed based on evidence related to 
        changes in patient outcomes, the Secretary shall--
                    ``(A) evaluate any new scientific studies on 
                changes in patient outcomes in relation to 
                susceptibility test interpretive criteria; and
                    ``(B) publish on the public Website of the Food and 
                Drug Administration a notice--
                            ``(i) presenting suggested new or updated 
                        interpretive criteria; and
                            ``(ii) if needed, hold a public advisory 
                        committee to discuss scientific evidence 
                        related to changes in interpretative criteria.
            ``(2) Annual compilation of notices.--Each year, the 
        Secretary shall compile the notices published under paragraph 
        (1)(B) noting any changes from prior notices and publish such 
        compilation in the Federal Register.
    ``(c) Definition.--In this section, the term `susceptibility test 
interpretive criteria' means one or more specific values which 
characterize patient outcomes in relation to the degree to which 
bacteria or other microbes are more resistant to treatment as measured 
by patient outcomes.''.
    (b) Conforming Amendment.--Section 1111 of the Food and Drug 
Administration Amendments Act of 2007 (42 U.S.C. 247d-5a; relating to 
identification of clinically susceptible concentrations of 
antimicrobials) is repealed.
    (c) Report to Congress.--Not later than one year after the date of 
enactment of this Act, the Secretary of Health and Human Services shall 
submit to the Committee on Energy and Commerce of the House of 
Representatives and the Committee on Health, Education, Labor, and 
Pensions of the Senate a report on the progress made in implementing 
section 511 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360a), as amended by this section.

SEC. 4. REQUIRING DEMONSTRATION OF SUPERIOR OUTCOMES FOR QUALIFIED 
              INFECTIOUS DISEASE PRODUCTS TO RECEIVE AN EXTENDED 
              EXCLUSIVITY PERIOD.

    Section 505E(g) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355f(g)) is amended by striking ``means an antibacterial or 
antifungal drug for human use intended to treat'' and inserting ``means 
an antibacterial or antifungal drug for human use that is demonstrated 
to produce superior outcomes over available therapies, based on direct 
measures of patient benefits in clinical trials, and that is intended 
to treat''.

SEC. 5. GUIDANCE ON TARGET PRODUCT PROFILES.

    Not later than 18 months after the date of enactment of this Act, 
the Commissioner of Food and Drugs, in consultation with the 
Administrator of the Centers for Medicare & Medicaid Services, the 
Director of the Indian Health Service, the Secretary of Defense, and 
the Secretary of Veterans Affairs, shall issue guidance on the 
development of target product profiles for novel antibacterial drugs 
focused on public health priorities.

A: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes.  To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Workplace Safety and Health 
Transparency Act of 2006''.

SEC. 2. ADOPTION OF NONGOVERNMENTAL STANDARDS UNDER THE OCCUPATIONAL 
              HEALTH AND SAFETY ACT.

    (a) Adoption by OSHA.--The Occupational Health and Safety Act of 
1970 (29 U.S.C. 651 et seq.) is amended by adding after section 6 the 
following:

                ``adoption of nongovernmental standards

    ``Sec. 6A.  (a) Effective on the date of enactment of this section, 
the Secretary shall not promulgate or incorporate by reference any 
finding, guideline, standard, limit, rule, or regulation based on a 
determination reached by any organization, unless the Secretary 
affirmatively finds that such determination--
            ``(1) has been adopted and promulgated by a nationally 
        recognized standards-producing organization under procedures 
        whereby it can be determined by the Secretary that persons 
        interested and affected by the scope or provisions of the 
        standard have reached substantial agreement on its adoption;
            ``(2) was formulated in a manner which afforded an 
        opportunity for diverse views to be considered; and
            ``(3) has been designated as such a standard by the 
        Secretary, after consultation with other appropriate Federal 
        agencies.
        Such finding and a summary of its basis shall be published in 
        the Federal Register and shall be considered a final action 
        subject to review by a United States District Court in 
        accordance with section 706 of title 5, United States Code.
    ``(b) With respect to rulemaking proceedings initiated by the 
Secretary but not finalized prior to the date of enactment of this 
section, the Secretary shall, within 180 days of the date of enactment 
of this section, investigate and identify the use of, influence of, or 
reliance upon any finding, guideline, standard, limit or any other 
recommendation that has not been made by an organization and procedure 
that does not comply with the requirements set forth in subsection (a). 
The Secretary shall publish the results of such investigations in the 
Federal Register and, in any final rule, standard, or official 
recommendation that is prescribed under such proceedings, shall not 
incorporate, use, or rely upon any finding, guideline, standard, limit, 
or other recommendation that does not comply with the requirements set 
forth in subsection (a). The Secretary's actions under this section 
shall be subject to review by a United States district court of 
appropriate jurisdiction.''.
    (b) Approval of State Plans.--Section 18 of the Occupational Safety 
and Health Act of 1970 (29 U.S.C. 667) is amended by adding at the end 
the following:
    ``(i) The Secretary shall not approve a State plan under this 
section that incorporates by reference any finding, guideline, 
standard, limit, rule, or regulation based on a determination reached 
by any organization, unless the Secretary determines that the standards 
adopted in such plan are standards that--
            ``(1) have been adopted and promulgated by a nationally 
        recognized standards-producing organization under procedures 
        whereby it can be determined by the State that persons 
        interested and affected by the scope or provisions of such 
        standards have reached substantial agreement on their adoption; 
        and
            ``(2) were formulated in a manner which afforded an 
        opportunity for diverse views to be considered.''.

SEC. 3. ADOPTION OF NONGOVERNMENTAL STANDARDS UNDER THE FEDERAL MINE 
              SAFETY AND HEALTH ACT.

    Section 101 of the Federal Mine Safety and Health Act of 1977 (30 
U.S.C. 811) is amended by adding at the end the following:
    ``(f)(1) Effective on the date of enactment of this section, the 
Secretary shall not promulgate or incorporate by reference any finding, 
guideline, standard, limit, rule, or regulation based on a 
determination reached by any organization, unless the Secretary 
affirmatively finds that such determination--
            ``(A) has been adopted and promulgated by a nationally 
        recognized standards-producing organization under procedures 
        whereby it can be determined by the Secretary that persons 
        interested and affected by the scope or provisions of the 
        standard have reached substantial agreement on its adoption;
            ``(B) was formulated in a manner which afforded an 
        opportunity for diverse views to be considered; and
            ``(C) has been designated as such a standard by the 
        Secretary, after consultation with other appropriate Federal 
        agencies.
Such finding and a summary of its basis shall be published in the 
Federal Register and shall be considered a final action subject to 
review by a United States District Court in accordance with section 706 
of title 5, United States Code.
    ``(2) With respect to rulemaking proceedings initiated by the 
Secretary but not finalized prior to the date of enactment of this 
subsection, the Secretary shall, within 180 days of the date of 
enactment of this subsection, investigate and identify the use of, 
influence of, or reliance upon any finding, guideline, standard, limit 
or any other recommendation that has not been made by an organization 
and procedure that does not comply with the requirements of paragraph 
(1). The Secretary shall publish the results of such investigations in 
the Federal Register and, in any final rule, standard, or 
recommendation that is prescribed under such proceedings, shall not 
incorporate, use, or rely upon any finding, guideline, standard, limit, 
or other official recommendation that does not comply with the 
requirements of paragraph (1). The Secretary's actions under this 
section shall be subject to review by a United States district court of 
appropriate jurisdiction.''.

A:
Workplace Safety and Health Transparency Act of 2006 - Amends the Occupational Health and Safety Act of 1970 and the Federal Mine Safety and Health Act of 1977 to prohibit the Secretary of Labor from promulgating or incorporating by reference, or approving occupational safety and health standards under a state plan that incorporates by reference, any finding, guideline, standard, limit, rule, or regulation based on a determination reached by any organization, unless the Secretary finds that such determination: (1) has been promulgated by a nationally recognized standards-producing organization under procedures whereby an opportunity was afforded for diverse views to be considered and whereby interested and affected persons substantial agreed on its adoption; and (2) in the case of a federal standard, has been designated as such a standard by the Secretary.
****